Media headlines about Minerva Neurosciences (NASDAQ:NERV) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Minerva Neurosciences earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.353888380692 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Minerva Neurosciences (NERV) opened at $6.65 on Tuesday. The stock has a market capitalization of $263.17, a P/E ratio of -5.94 and a beta of 1.53. Minerva Neurosciences has a 12 month low of $4.80 and a 12 month high of $11.15.
Minerva Neurosciences (NASDAQ:NERV) last announced its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter. During the same period in the previous year, the firm posted ($0.24) earnings per share. equities analysts predict that Minerva Neurosciences will post -1.28 earnings per share for the current year.
In related news, CFO Geoff Race sold 5,829 shares of the business’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $5.79, for a total transaction of $33,749.91. Following the completion of the transaction, the chief financial officer now owns 197,698 shares in the company, valued at approximately $1,144,671.42. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last quarter, insiders sold 12,590 shares of company stock valued at $73,073. Company insiders own 21.60% of the company’s stock.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.